(2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid
C21H21N5O3 — CID 118306060
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid
(2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid (PubChem CID 118306060) has the molecular formula C21H21N5O3 and a molecular weight of 391.43 g/mol. Its IUPAC name is (2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid.
Molecular Properties
| Compound Name | (2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid |
|---|---|
| PubChem CID | 118306060 |
| Molecular Formula | C21H21N5O3 |
| Molecular Weight | 391.43 g/mol |
| Exact Mass | 391.16 |
| IUPAC Name | (2S)-6-(1-cyclopropylpyrazol-4-yl)-2-methyl-5-pyrazin-2-yloxy-3,4-dihydro-2H-quinoline-1-carboxylic acid |
| SMILES | C[C@H]1CCc2c(ccc(-c3cnn(C4CC4)c3)c2Oc2cnccn2)N1C(=O)O |
| InChI | InChI=1S/C21H21N5O3/c1-13-2-5-17-18(26(13)21(27)28)7-6-16(14-10-24-25(12-14)15-3-4-15)20(17)29-19-11-22-8-9-23-19/h6-13,15H,2-5H2,1H3,(H,27,28)/t13-/m0/s1 |
| InChIKey | ZJMYSLOAJWNAEJ-ZDUSSCGKSA-N |
| XLogP | 4.29 |
| TPSA | 93.37 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 391.43 |
| LogP ≤ 5 | 4.29 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118306060 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.